Literature DB >> 23498779

Transplantation for inherited metabolic disorders of the liver.

M L Schilsky1.   

Abstract

Inherited metabolic diseases that affect the liver are a frequent cause of liver failure in children, but other disorders more commonly cause liver failure in adulthood where they may present with chronic liver disease and, less frequently, with acute liver failure. The identification of the underlying genetic defect for many of these inherited disorders has improved our understanding of their pathophysiology and impacted on the indications for and timing of liver transplant, yielding better outcomes. Screening for disease and genetic counseling of family members may help prevent adverse outcomes in relatives of affected individuals. Timely liver transplantation offers correction of the inherited metabolic defect and restores liver function when medical therapy is not possible or when complications of liver disease arise. Some inherited metabolic diseases have their defect based in the liver and lead not to liver disease, but to other end organ damage. Earlier detection of these disorders may prevent pathological injury by treatment of the underlying disease or by pre-emptive liver transplant. In some instances where damage of other organs has already occurred, dual organ transplant with liver and another organ may be needed. Improvement in the technical aspects of performing liver transplantation and posttransplant care has led to better outcomes for those with inherited metabolic disorders of the liver.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23498779     DOI: 10.1016/j.transproceed.2013.02.001

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  6 in total

Review 1.  Transplantation as disease modifying therapy in adults with inherited metabolic disorders.

Authors:  Sandra Sirrs; Fady Hannah-Shmouni; Stephen Nantel; James Neuberger; Eric M Yoshida
Journal:  J Inherit Metab Dis       Date:  2018-02-01       Impact factor: 4.982

Review 2.  Wilson's disease and other neurological copper disorders.

Authors:  Oliver Bandmann; Karl Heinz Weiss; Stephen G Kaler
Journal:  Lancet Neurol       Date:  2015-01       Impact factor: 44.182

Review 3.  Nuclease-Mediated Gene Therapies for Inherited Metabolic Diseases of the Liver.

Authors:  Taylor E Bryson; Caitlin M Anglin; P Hudson Bridges; Renee N Cottle
Journal:  Yale J Biol Med       Date:  2017-12-19

Review 4.  Nutritional Therapy in Liver Transplantation.

Authors:  Ahmed Hammad; Toshimi Kaido; Vusal Aliyev; Claudia Mandato; Shinji Uemoto
Journal:  Nutrients       Date:  2017-10-16       Impact factor: 5.717

Review 5.  Using CRISPR/Cas9 to model human liver disease.

Authors:  Michele Alves-Bezerra; Nika Furey; Collin G Johnson; Karl-Dimiter Bissig
Journal:  JHEP Rep       Date:  2019-10-25

6.  Reprogramming metabolic pathways in vivo with CRISPR/Cas9 genome editing to treat hereditary tyrosinaemia.

Authors:  Francis P Pankowicz; Mercedes Barzi; Xavier Legras; Leroy Hubert; Tian Mi; Julie A Tomolonis; Milan Ravishankar; Qin Sun; Diane Yang; Malgorzata Borowiak; Pavel Sumazin; Sarah H Elsea; Beatrice Bissig-Choisat; Karl-Dimiter Bissig
Journal:  Nat Commun       Date:  2016-08-30       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.